Effective short-term treatment of generalized anxiety disorder with trifluoperazine. 1986

J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed

The effectiveness of trifluoperazine in daily doses of 2 to 6 mg in the short-term treatment of generalized anxiety disorder was evaluated in 415 outpatients in a double-blind, placebo-controlled, multicenter trial. Efficacy and side effects were assessed by a number of psychiatric rating scales for anxiety. All efficacy measurements of anxiety were significantly improved (p less than .001) with trifluoperazine compared to placebo by the end of the study. The side effects profile of trifluoperazine and placebo were similar during the 4-week treatment period.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
March 2000, International clinical psychopharmacology,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
January 2018, PloS one,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
January 2004, Primary care companion to the Journal of clinical psychiatry,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
January 2017, Case reports in psychiatry,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
May 2002, International clinical psychopharmacology,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
January 2002, The Journal of clinical psychiatry,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
April 2007, Neuropsychiatric disease and treatment,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
December 1987, The Journal of clinical psychiatry,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
January 2024, Frontiers in psychiatry,
J Mendels, and T F Krajewski, and V Huffer, and R J Taylor, and S Secunda, and A Schless, and J A Sebastian, and G Semchyshyn, and M J Durr, and A S Melmed
April 2004, European psychiatry : the journal of the Association of European Psychiatrists,
Copied contents to your clipboard!